Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJohad Khoury
Assistant Professor AdjunctAbout
Research
Publications
2026
Vascular Endothelial Growth Factor-D Improves Lung Vascular Integrity During Acute Lung Injury
Yoon Y, Sharma L, Tang W, Kirk S, Raredon M, Ahangari F, Khoury J, Qian H, Ke Y, Tulapurkar M, Liu R, Luan Y, Yuan Q, Chen L, Birukov K, Simons M, Wu D, Niklason L, Kaminski N, Yuan Y. Vascular Endothelial Growth Factor-D Improves Lung Vascular Integrity During Acute Lung Injury. Circulation Research 2026, 138: e326094. PMID: 41822962, PMCID: PMC13007730, DOI: 10.1161/circresaha.124.326094.Peer-Reviewed Original ResearchVEGF-DAcute lung injuryBarrier-protective effectsVascular integrityLung injuryLipopolysaccharide-induced acute lung injury modelIntravenous administrationTNF-aParacrine signalingModel of acute lung injuryPulmonary vascular integrityLigand-receptor interactionsImmune cell infiltrationAcute lung injury modelLung vascular integrityVEGFR2-dependent signalingLung injury modelEndothelial barrier integrityEndothelial barrier functionRNA sequencing dataMicrovascular endothelial cellsInhibition of VEGFR2Microvascular nichePharmacological blockadeAssociated with pathwaysEpidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury
Harris Z, Korde A, Khoury J, Manning E, Stanley G, Shin Y, Mitchell K, von der Schulenburg A, Sun Y, Hu B, Shin H, Joerns J, Clark B, Placek L, Unutmaz D, Moldobaeva A, Sharma L, Sauler M, Rajagopalan G, Zhang X, Wang H, Ghaedi M, Kang M, Koff J. Epidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury. BMJ Open Respiratory Research 2026, 13: e003323. PMID: 41592865, PMCID: PMC12853440, DOI: 10.1136/bmjresp-2025-003323.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorAcute lung injuryHyperoxic ALIHyperoxic acute lung injuryGrowth factor receptorIn vivo effectsLung injuryOxidant-mediated acute lung injuryFactor receptorIntensive care unit mortalityExposure to high oxygenAlveolar type II cellsDelivery of supplemental oxygenPulmonary cell deathLife-saving therapyPluripotent stem cellsType II cellsNormoxia controlSupplemental oxygenUnit mortalityAlveolar epitheliumBeclin-1Cell death pathwaysStem cellsTherapeutic potentialPulmonary hypertension associated with nonparenchymal restrictive lung diseases
Jutant E, Humbert M, Montani D, Khoury J, Adir Y. Pulmonary hypertension associated with nonparenchymal restrictive lung diseases. European Respiratory Review 2026, 35: 250187. PMID: 41813013, PMCID: PMC12976881, DOI: 10.1183/16000617.0187-2025.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPulmonary hypertensionRestrictive lung diseaseLung diseaseAssociated with chronic lung diseaseGroup 3 PHPulmonary arterial hypertensionCombined pulmonary fibrosisInterstitial lung diseaseChronic lung diseaseHypoventilation syndromeArterial hypertensionVentilatory disordersClinical manifestationsPulmonary fibrosisMechanisms of PHPathophysiological mechanismsDisease subgroupsDiseaseHypertensionLungSubgroupsPneumonectomyHypoventilationFibrosisPatients
2025
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling
Kim S, Nouws J, Ruwisch J, Woodard G, Cooley J, Khoury J, Sun H, Doherty E, Piecychna M, Manning E, Kang M, Bruscia E, Wei H, Zhang Y, Yarovinsky T, Hwa J, Zacharias W, Ingram J, Lee C, Elias J, Kaminski N, Redente E, Herzog E, Prasse A, Bucala R, Sauler M. Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling. Science Translational Medicine 2025, 17: eadr2277. PMID: 41337540, DOI: 10.1126/scitranslmed.adr2277.Peer-Reviewed Original ResearchMeSH KeywordsAlveolar Epithelial CellsAnimalsAntigens, Differentiation, B-LymphocyteBleomycinDisease Models, AnimalHistocompatibility Antigens Class IIHumansIdiopathic Pulmonary FibrosisIntramolecular OxidoreductasesLungMacrophage Migration-Inhibitory FactorsMacrophagesMaleMiceMice, Inbred C57BLMice, TransgenicProteasome Endopeptidase ComplexProteostasisSignal TransductionUbiquitinConceptsIdiopathic pulmonary fibrosisMacrophage migration inhibitory factorBronchoalveolar lavage fluidPharmacological inhibition of MIFBleomycin-induced lung injury modelMouse modelPharmacological inhibitionC-X3-C motif chemokine receptor 1Human precision-cut lung slicesTransforming growth factor-b1Inhibition of macrophage migration inhibitory factorSignals to macrophagesPrecision-cut lung slicesFibrotic lung diseaseType 2 epithelial cellsAlveolar type 2 epithelial cellsChemokine receptor 1Lung injury modelMigration inhibitory factorMIF-2Study participantsUbiquitin-proteasome systemSpontaneous fibrosisPulmonary fibrosisLavage fluidSeparation of telomere protection from length regulation by two different point mutations at amino acid 492 of RTEL1
Smoom R, May C, Lichtental D, Bar-Ness K, Rangel R, Khoury J, Nachmani D, Avrahami D, Ahangari F, Skordalakes E, Kaminski N, Kaestner K, Tzfati Y. Separation of telomere protection from length regulation by two different point mutations at amino acid 492 of RTEL1. Nucleic Acids Research 2025, 53: gkaf507. PMID: 40530700, PMCID: PMC12203905, DOI: 10.1093/nar/gkaf507.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAnimalsDisease Models, AnimalDNA DamageDNA HelicasesDyskeratosis CongenitaFetal Growth RetardationGrowth DisordersHematopoiesisHumansIntellectual DisabilityLimb Deformities, CongenitalLungMiceMicrocephalyPoint MutationTelomereTelomere HomeostasisX-Linked Intellectual DisabilityConceptsHoyeraal-Hreidarsson syndromeTelomere protectionLength regulationTelomere length regulationTelomere-related diseasesTelomere biology disordersDNA helicaseMouse genomeGenome stabilityMouse modelMouse telomeresAberrant hematopoiesisGenomic instabilityPoint mutationsHouse miceTelomeric DNA damageAnaphase bridgesRTEL1Amino acidsTelomereMechanistic rolesDNA damageMutationsIsoleucine mutationGenomeTicagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
Bahouth F, Chutko B, Sholy H, Hassanain S, Zaid G, Radzishevsky E, Fahmwai I, Hamoud M, Samnia N, Khoury J, Dobrecky-Mery I. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines 2025, 12: 13. PMID: 40407605, PMCID: PMC12194868, DOI: 10.3390/medicines12020013.Peer-Reviewed Original ResearchAcute coronary syndromeCoronary syndromeAntiplatelet drugsCardiovascular deathComposite endpoint of cardiovascular deathAdmitted with acute coronary syndromeEndpoint of cardiovascular deathTreated with ticagrelorTreated with prasugrelSingle-center studyRetrospective observational studyRecurrent cardiac eventsDual antiplatelet drugsReal-world treatmentPercutaneous coronary interventionBARC classificationSignificant bleedingPrasugrel groupPrimary endpointP2Y12 inhibitorsNo significant differenceACS patientsCardiac eventsComposite endpointPrasugrelToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: 91-102. PMID: 39189851, PMCID: PMC11755360, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse model
2023
Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study
Najjar-Debbiny R, Barnett-Griness O, Khoury J, Gronich N, Weber G, Adir Y, Shteinberg M, Shneir S, Sharma L, Saliba W. Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study. The American Journal Of Medicine 2023, 136: 1087-1093.e2. PMID: 37598922, DOI: 10.1016/j.amjmed.2023.07.020.Peer-Reviewed Original ResearchPulmonary fibrosisCase-control studyCOVID-19 severityCOVID-19Multivariable conditional logistic regression modelsNested Case-Control StudyConditional logistic regression modelsSevere COVID-19Prior COVID-19COVID-19 infectionLogistic regression modelsLargest healthcare providerUnderlying cohortCohort entrySignificant morbiditySurveillance biasOdds ratioSevere diseaseFibrosisHealthcare providersCoronavirus diseaseCalendar timePatientsCohortLag timeImpact of Adherence to Continuous Positive Airway Pressure on Outcomes in Obstructive Sleep Apnea Chronic Obstructive Pulmonary Disease Overlap Syndrome
Khoury J, Hakim F. Impact of Adherence to Continuous Positive Airway Pressure on Outcomes in Obstructive Sleep Apnea Chronic Obstructive Pulmonary Disease Overlap Syndrome. American Journal Of Respiratory And Critical Care Medicine 2023, 207: 221-222. PMID: 36049224, PMCID: PMC9893331, DOI: 10.1164/rccm.202207-1403le.Commentaries, Editorials and Letters
2022
Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients?
Khoury J, Ghersin I, Braun E, Elias A, Aronson D, Azzam Z, Bahouth F. Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients? Israel Medical Association Journal 2022, 24: 757-762. PMID: 36436045.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureAngiotensin receptor blockersPatients 80 yearsEjection fractionHeart failureMedicine groupSingle-center retrospective studyDecompensated heart failureReduced ejection fractionLarge prospective studiesRandomized clinical trialsOlder adult populationGDMT groupMineralocorticoid antagonistsCause mortalityReceptor blockersValue of guidelinesElderly patientsHospital dischargeOlder patientsYounger patientsMedical therapyPrimary outcomeProspective studyRetrospective study